Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Thompson, AJ; Shiffman, ML; Rossaro, L; Ghalib, R; Han, S-HB; Beavers, KL; Pianko, S; George, J; He, L; Wu, X; Flores, N; Pang, PS; Rossi, SJ; McHutchison, JG; Lee, SS; Muir, AJ

Published Date

  • October 1, 2012

Published In

Volume / Issue

  • 56 /

Start / End Page

  • 556A - 557A

Published By


  • 2

International Standard Serial Number (ISSN)

  • 0270-9139

Conference Name

  • 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)

Conference Location

  • Boston, MA

Conference Start Date

  • November 9, 2012

Conference End Date

  • November 13, 2012